primary biliary cholangitis

Gilead’s Livdelzi shows promise in PBC clinical trial
Clinical Trials Arena
Mon, 11/18/24 - 11:08 am
Gilead Sciences
Livdelzi
primary biliary cholangitis
clinical trials
FDA declines full approval for Intercept's liver disease drug
Pharma Live
Tue, 11/12/24 - 11:10 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
liver disease
FDA Pushes Back PDUFA Dates for Amgen and Intercept
BioSpace
Fri, 10/18/24 - 11:28 am
FDA
Amgen
Lumakras
colorectal cancer
Intercept Pharma
Ocaliva
primary biliary cholangitis
FDA extends review of Obeticholic Acid (Ocaliva) sNDA for primary biliary cholangitis
HCP Live
Thu, 10/17/24 - 08:28 pm
Ocaliva
Intercept Pharma
primary biliary cholangitis
FDA
Intercept's liver med Ocaliva takes heat at FDA expert meeting, as hopes for full approval dim
Fierce Pharma
Mon, 09/16/24 - 10:54 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
US FDA staff questions confirmatory trial data for Intercept's liver disease drug
Reuters
Wed, 09/11/24 - 11:51 am
FDA
Intercept Pharma
Ocaliva
clinical trials
primary biliary cholangitis
liver disease
Gilead’s Livdelzi (Seladelpar) for Primary Biliary Cholangitis Promises Pruritus Reduction
Xtalks
Thu, 08/22/24 - 10:00 pm
FDA
Livdelzi
Gilead Sciences
primary biliary cholangitis
FDA approves Gilead's seladelpar for primary biliary cholangitis
First Word Pharma
Wed, 08/14/24 - 10:35 pm
Gilead Sciences
seladelpar
Livdelzi
liver disease
primary biliary cholangitis
Calliditas' liver disease trial hits primary endpoint after sweeping changes to design
Fierce Biotech
Fri, 07/26/24 - 11:08 am
Calliditas
liver disease
primary biliary cholangitis
clinical trials
setanaxib
Gilead, Ipsen build the case for their PBC drugs at EASL
Pharmaphorum
Wed, 06/5/24 - 11:06 am
Gilead Sciences
Ipsen
primary biliary cholangitis
seladelpar
EASL
elafibranor
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
FDA adds new 'do not use' note to Intercept's Ocaliva label after a slew of side effect reports in cirrhosis patients
Endpoints
Thu, 05/27/21 - 11:06 am
Intercept Pharma
NASH
Ocaliva
FDA
primary biliary cholangitis
Rose-tinted glasses might not save Genkyotex
EP Vantage
Thu, 05/2/19 - 11:10 am
Genkyotex
primary biliary cholangitis
GKT831
clinical trials
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
BioSpace
Wed, 04/24/19 - 11:58 am
Genfit
breakthrough therapy
FDA
primary biliary cholangitis
elafibranor
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Fierce Biotech
Thu, 04/18/19 - 10:21 am
Genfit
FDA
primary biliary cholangitis
elafibranor
clinical trials
GenFit gets $135M Nasdaq IPO for NASH, PBC hopes
Fierce Biotech
Wed, 03/27/19 - 10:21 am
Genfit
IPOs
NASH
primary biliary cholangitis
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
CP Wire
Tue, 11/13/18 - 10:26 am
CymaBay
seladelpar
primary biliary cholangitis
NASH
CymaBay Therapeutics Reports Positive Results from Ph II Study of Seladelpar in Patients with Primary Biliary Cholangitis
Tue, 11/13/18 - 10:02 am
CymaBay
seladelpar
primary biliary cholangitis
NASH

Pages